Gene
KDR
KDR is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (81), Actionable biomarkers (1), Trial mentions (87), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention KDR. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 51 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 136 of 11,460 | 1.19% |
| 2022 | 2 of 8,285 | 0.02% | 152 of 13,598 | 1.12% |
| 2021 | 1 of 8,692 | 0.01% | 169 of 15,045 | 1.12% |
| 2020 | 2 of 7,640 | 0.03% | 178 of 14,459 | 1.23% |
| 2019 | 3 of 7,300 | 0.04% | 138 of 12,159 | 1.13% |
| 2018 | 1 of 6,927 | 0.01% | 120 of 11,854 | 1.01% |
| 2017 | 0 of 6,558 | 0.00% | 111 of 11,595 | 0.96% |
Showing 10 of 37 years.
Assay-provider ledger (81)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Fischer Scientific/ProcartaPlex (Hampton, NH) | Reagent supplier | Clinical validation | 1 | September 01, 2025 |
| QUANSYS Biosciences | Reagent supplier | Clinical validation | 1 | September 01, 2025 |
| BIOMERIEUX | Diagnostic provider | Clinical validation | 1 | August 01, 2025 |
| RayBiotech | Reagent supplier | Clinical validationAnalytical validation | 1 | October 01, 2023 |
| Becton Dickinson, NJ, USA (BACTEC 460 culture system and sample collection tubes) | Context dependent | Clinical validation | 1 | May 01, 2021 |
Showing 5 of 81 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| KDR (A1065T) | Vegfr Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (87)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02694575 | Trial biospecimen (AACT) |
| NCT00126503 | Trial eligibility (AACT) |
| NCT00324597 | Trial eligibility (AACT) |
| NCT00436709 | Trial eligibility (AACT) |
| NCT06904300 | Trial eligibility (AACT) |
Showing 5 of 87 trial mentions.
Target-disease associations (845)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1,3,7-trimethylurate measurement | measurement | GWAS credible sets |
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
Showing 5 of 845 associations.
Vendor sourcing (188)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AIDS Malignancy Consortium | Trial sponsor | Mentioned in trial textTrial free-text mention | VEGFR2 | View trial NCT00686842 |
| AVEO Oncology (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | VEGFR2 | View trial NCT01782313 |
| AVEO Oncology (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | Vascular endothelial growth factor receptor 2 | View trial NCT01478594 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | VEGFR2 | View trial NCT01253668 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.3475C>T (p.H1159Y) alteration is located in exon 26 (coding exon 26) of the KDR gene. This alteration results from a C to T substitution at nucleotide ... | View ClinVar record SCV003543244.2 |
Showing 5 of 188 sourcing records.
Trial-cited literature (2,091)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. | Pediatric cardiology | 2026 | 0 |
| Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 50 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. | The Lancet. Oncology | 2025 | 14 |
| Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. | The oncologist | 2025 | 9 |
| Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. | The Journal of clinical endocrinology and metabolism | 2025 | 8 |
Showing 5 of 2,091 papers.
Protein variant mentions (25)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A10M | 1 | 2011 | PMID 21224376 |
| p.A15M | 1 | 2011 | PMID 21224376 |
| p.A16F | 1 | 2011 | PMID 21224376 |
| p.A18F | 1 | 2011 | PMID 21224376 |
| p.A19F | 1 | 2011 | PMID 21224376 |
Showing 5 of 25 variants.
Literature-extracted relations (375)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| SUNITINIB | Chemical | associate |
Genetic polymorphisms of <i>VEGFR2</i> and <i>FGFR2</i> genes are associated with exposure to sunitinib and cardiovascular toxicity. | 2025 |
| EVEROLIMUS | Chemical | negative_correlate |
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. | 2025 |
| Sorafenib | Chemical | negative_correlate |
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. | 2025 |
| SUNITINIB | Chemical | negative_correlate |
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial. | 2024 |
| Sorafenib | Chemical | associate |
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial. | 2023 |
Showing 5 of 375 relation assertions.
Organizations publishing (987)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 93 | 2006 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 93 | 2009 to 2025 |
| The University of Texas System | Academic | 79 | 1995 to 2025 |
| Harvard Medical School | Academic | 67 | 2001 to 2025 |
| Mass General Brigham | Hospital | 66 | 2001 to 2025 |
Showing 5 of 987 organizations.
Where KDR appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
651 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.